Analysis and therapy of renal tubular dysgenesis-causing AGT deletion/insertion mutation conditional knock-out mice

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

Analysis and therapy of renal tubular dysgenesis-causing AGT deletion/insertion mutation conditional knock-out mice

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Shih-Hua Lin l521116@gmail.com Tri-Service General Hospital Medicine Taiipei City Taiwan -

Co-author 2

Min-Hua Tseng doc31089@gmail.com Chang Gung Memorial Hospital Pediatric Taoyuan City Taiwan *

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

This study assessed dexamethasone as rescue therapy for fatal autosomal recessive renal tubular dysgenesis (ARRTD) due to AGT mutation, with conditional knockout mice enabling targeted investigation of AGT’s role and precise evaluation of treatment.

Methods

A novel homozygous AGTE3-4del/E3-4del conditional knock-in mouse model, bearing a 2870 bp deletion encompassing exons 3 and 4 of AGT, was used to evaluate the in vivo therapeutic impact of prenatal dexamethasone administration.

Results

AGTE3-4del/E3-4del mice exhibited classic features of ARRTD, including hypotension, elevated serum creatinine and urea, and high postnatal mortality, reduced body weight, electrolyte disturbances, and impaired urine concentration. Histological analysis revealed defective proximal tubular development and pronounced renal dysgenesis. Molecular studies demonstrated almost absent hepatic AGT mRNA and protein expression, accompanied by decreased circulating AGT and angiotensin II levels, and a significant increase in renin concentrations. Prenatal dexamethasone treatment enhanced hepatic AGT production, reduced renin, and partially restored proximal tubule maturation of AGTE3-4del/E3-4delmice, demonstrating beneficial effects on both renal development and molecular abnormalities in this fatal genetic model.

Conclusion

AGT is very crucial in maintaining renin-angiotensin system homeostasis and supporting normal kidney development. Antenatal dexamethasone administration can partially ameliorate renal and molecular abnormalities caused by AGT mutation-induced ARRTD.

Kewords